Drug Profile
MT 7529
Alternative Names: H7 vaccine; H7 VLP influenza vaccine - Medicago; H7N9 vaccine - Medicago; H7N9 VLP vaccine with GLA adjuvant - Medicago; MT-7529; Plant-based H7N9 VLP vaccine - Medicago; Plant-made H7 virus-like particle influenza vaccine - MedicagoLatest Information Update: 17 Feb 2023
Price :
$50
*
At a glance
- Originator Medicago
- Class Influenza A virus H7N9 vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H7N9 subtype
Most Recent Events
- 17 Feb 2023 Discontinued - Phase-I for Influenza A virus H7N9 subtype (Prevention) in Canada (IM) (Mitsubishi Tanabe Pharma Corporation pipeline, February 2023)
- 22 Oct 2021 Phase-I development is still ongoing in Influenza-A virus H7N9 subtype (Prevention) in Canada (IM,Injection) (Mitsubishi Tanabe Pharmaceutical's pipeline, October 2021)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Influenza-A virus H7N9 subtype(Prevention) in Canada (IM, Injection)